Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Intensive Care and Department of Paediatric Surgery, Erasmus MC-Sophia Childrens Hospital, Rotterdam, The Netherlands.
Arch Toxicol. 2021 Sep;95(9):3015-3029. doi: 10.1007/s00204-021-03115-y. Epub 2021 Jul 15.
Variation in the efficacy and safety of central nervous system drugs between humans and rodents can be explained by physiological differences between species. An important factor could be P-glycoprotein (Pgp) activity in the blood-brain barrier (BBB), as BBB expression of this drug efflux transporter is reportedly lower in humans compared to mouse and rat and subject to an age-dependent increase. This might complicate animal to human extrapolation of brain drug disposition and toxicity, especially in children. In this study, the potential species-specific effect of BBB Pgp activity on brain drug exposure was investigated. An age-dependent brain PBPK model was used to predict cerebrospinal fluid and brain mass concentrations of Pgp substrate drugs. For digoxin, verapamil and quinidine, in vitro kinetic data on their transport by Pgp were derived from literature and used to scale to in vivo parameters. In addition, age-specific digoxin transport was simulated for children with a postnatal age between 25 and 81 days. BBB Pgp activity in the model was optimized using measured CSF data for the Pgp substrates ivermectin, indinavir, vincristine, docetaxel, paclitaxel, olanzapine and citalopram, as no useful in vitro data were available. Inclusion of Pgp activity in the model resulted in optimized predictions of their brain concentration. Total brain-to-plasma AUC values (Kp,brain) in the simulations without Pgp were divided by the Kp,brain values with Pgp. Kp ratios ranged from 1 to 45 for the substrates investigated. Comparison of human with rodent Kp,brain ratios indicated ≥ twofold lower values in human for digoxin, verapamil, indinavir, paclitaxel and citalopram and ≥ twofold higher values for vincristine. In conclusion, BBB Pgp activity appears species-specific. An age-dependent PBPK model-based approach could be useful to extrapolate animal data to human adult and paediatric predictions by taking into account species-specific and developmental BBB Pgp expression.
中枢神经系统药物在人体和啮齿动物中的疗效和安全性的差异可以用物种间的生理差异来解释。一个重要因素可能是血脑屏障 (BBB) 中的 P-糖蛋白 (Pgp) 活性,据报道,这种药物外排转运体在人类 BBB 中的表达低于小鼠和大鼠,并随年龄增长而增加。这可能会使动物到人类的脑药物分布和毒性外推复杂化,尤其是在儿童中。在这项研究中,研究了 BBB Pgp 活性对脑药物暴露的潜在种属特异性影响。使用依赖年龄的脑 PBPK 模型来预测 Pgp 底物药物的脑脊液和脑质量浓度。对于地高辛、维拉帕米和奎尼丁,从文献中得出了它们通过 Pgp 转运的体外动力学数据,并将其用于体内参数的比例。此外,还模拟了出生后 25 至 81 天之间的儿童的地高辛特定年龄的转运。使用伊维菌素、茚地那韦、长春新碱、多西紫杉醇、紫杉醇、奥氮平和西酞普兰的 Pgp 底物的测量 CSF 数据对模型中的 BBB Pgp 活性进行了优化,因为没有有用的体外数据。在模型中包含 Pgp 活性导致对其脑浓度的优化预测。没有 Pgp 的模拟中的总脑-血浆 AUC 值 (Kp,brain) 除以有 Pgp 的 Kp,brain 值。研究的底物的 Kp 比值范围为 1 至 45。将人与啮齿动物的 Kp,brain 比值进行比较表明,地高辛、维拉帕米、茚地那韦、紫杉醇和西酞普兰在人体内的比值低 2 倍以上,长春新碱的比值高 2 倍以上。总之,BBB Pgp 活性似乎具有种属特异性。基于依赖年龄的 PBPK 模型的方法可以通过考虑种属特异性和发育性 BBB Pgp 表达,将动物数据外推到人类成人和儿科预测。